Market Overview

UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight on Asset Quality

Share:
Related NBIX
Neurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out
15 Biggest Mid-Day Losers For Wednesday

Morgan Stanley initiated its coverage on Neurocrine Biosciences (NASDAQ: NBIX) with an Overweight rating and a $12 price target.

Morgan Stanley said, "Neurocrine has a differentiated lead asset, elagolix, targeting large markets with segments of unmet need. We believe the Street undervalues this asset. We expect elagolix success in endometriosis and uterine fibroids (UF) and model combined WW sales of ~$720mn in 2020."

Neurocrine Biosciences closed at $8.30 on Wednesday.

Latest Ratings for NBIX

DateFirmActionFromTo
May 2017Bank of AmericaInitiates Coverage OnBuy
Jan 2017OppenheimerUpgradesPerformOutperform
Nov 2016OppenheimerInitiates Coverage OnPerform

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (NBIX)

View Comments and Join the Discussion!